MedTrace Logo

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

NCT05877651 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-05-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients with metastatic or recurrent solid tumors who failed standard therapy.

Conditions

Interventions

BIOLOGICAL

MASCT-I injection

The final products of MASCT-I technology are dendritic cells (DC) and effector T cells

Sponsors & Collaborators

  • HRYZ Biotech Co.

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu, Doctor · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-21
Primary Completion
2021-10-15
Completion
2021-10-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05877651 on ClinicalTrials.gov